Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo

Stock Track01-02

HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application (NDA) for the combination of ORPATHYS® and TAGRISSO® in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy has been accepted and granted priority review status by the China National Medical Products Administration (NMPA).

The NDA submission was supported by data from the SACHI Phase III trial, which evaluated the efficacy and safety of the ORPATHYS® and TAGRISSO® combination compared to standard chemotherapy. The study met its primary endpoint of progression-free survival in a planned interim analysis, leading to the early conclusion of enrollment.

According to Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED, the combination has demonstrated clear evidence to address MET-driven EGFR-inhibitor resistance and offers a continued path for oral treatment. The company hopes to bring this all-oral, chemotherapy-free treatment option to patients with MET-driven lung cancer in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154742837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154742837","market":"us","top_or_hot":-1,"title":"Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo","media":"Stock Track","content":"<p>HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application (NDA) for the combination of ORPATHYS® and TAGRISSO® in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy has been accepted and granted priority review status by the China National Medical Products Administration (NMPA).</p>\n\n<p>The NDA submission was supported by data from the SACHI Phase III trial, which evaluated the efficacy and safety of the ORPATHYS® and TAGRISSO® combination compared to standard chemotherapy. The study met its primary endpoint of progression-free survival in a planned interim analysis, leading to the early conclusion of enrollment.</p>\n\n<p>According to Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED, the combination has demonstrated clear evidence to address MET-driven EGFR-inhibitor resistance and offers a continued path for oral treatment. The company hopes to bring this all-oral, chemotherapy-free treatment option to patients with MET-driven lung cancer in the near future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-02 09:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application (NDA) for the combination of ORPATHYS® and TAGRISSO® in lung ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1154742837","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154742837","pubTimestamp":1735781560,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application  for the combination of ORPATHYS and TAGRISSO in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy has been accepted and granted priority review status by the China National Medical Products Administration .The NDA submission was supported by data from the SACHI Phase III trial, which evaluated the efficacy and sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"肺癌药物组合监管利好消息推动和黄医药股价飙升5.99%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"HUTCHMED's stock surged 5.99% in the pre-market session on Thursday, following the announcement that the company's New Drug Application (NDA) for the combination of ORPATHYS® and TAGRISSO® in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy has been accepted and granted priority review status by the China National Medical Products Administration (NMPA).\nThe NDA submission was supported by data from the SACHI Phase III trial, which evaluated the efficacy and safety of the ORPATHYS® and TAGRISSO® combination compared to standard chemotherapy. The study met its primary endpoint of progression-free survival in a planned interim analysis, leading to the early conclusion of enrollment.\nAccording to Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED, the combination has demonstrated clear evidence to address MET-driven EGFR-inhibitor resistance and offers a continued path for oral treatment. The company hopes to bring this all-oral, chemotherapy-free treatment option to patients with MET-driven lung cancer in the near future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154742837"}